Avita Medical-Nachfolgethread-AvitaTherapeutics
Seite 1 von 2 Neuester Beitrag: 26.11.21 12:00 | ||||
Eröffnet am: | 26.07.20 09:50 | von: Medical | Anzahl Beiträge: | 28 |
Neuester Beitrag: | 26.11.21 12:00 | von: Medical | Leser gesamt: | 6.337 |
Forum: | Hot-Stocks | Leser heute: | 6 | |
Bewertet mit: | ||||
Seite: < 1 | 2 > |
https://www.ariva.de/forum/...l-patentrecht-auf-recell-funhale-384509
https://www.ariva.de/forum/...-recell-funhale-384509?page=1#jumppos34
und einem Link zu Avita Therapeuthics ADR -> stockwatch.com > 1 Year Chart
https://www.stockwatch.com/Chart/...me=1&symbol=RCEL®ion=U
Quelle: s.oben
Quelle:https://plastische-frankfurt.de/eingriff/frau/...irn-und-augenbrauen/
U.S based RECELL® revenue is expected to be $5.0 million in the second quarter of 2021 ended December 31, 2020, compared to $5.0 million in the previous quarter. U.S based RECELL revenue increased $1.9 million or 62% over the same quarter in the prior year.
Total global revenue is expected to be $5.1 million in the second quarter of 2021, compared to $5.1 million in the previous quarter. Total global revenue increased $1.8 million in the current quarter or 57% over the same quarter in the prior year.
The Company had cash of approximately $59.8 million, a decrease of $6.0 million or 9% over the $65.8 million held at the end of the previous quarter....."Ende Zitat
full Source:https://www.stockwatch.com/News/...10112&symbol=RCEL®ion=U
6th January, 2021* 7.73%
Change §
1 day 0.13
1 week 0.29
1 month -0.38
Stock information
ASX AVH
§
Source:https://www.shortman.com.au/stock?q=avh
Quelle/Chart:https://www.barchart.com/stocks/quotes/RCEL/interactive-chart
Type Value Conf.§
resist. 28.86 3
resist. 27.20 2
resist. 26.08 4
resist. 24.52 5
resist. 24.05 4
resist. 23.22 7 < !
supp 21.87 2
supp 21.25 2
supp 20.72 4
supp 19.87 9
supp 17.59 6
Quelle:http://www.stockta.com/cgi-bin/analysis.pl?symb=RCEL
Recent Trades - Last 10 of 98 (19.01.2021 )<16.00 MEZ
Time ET Ex Price Change Volume
09:35:38 Q 23.70 0.95 100 §
09:35:38 Q 23.68 0.93 100 §
09:35:38 Q 23.67 0.92 100 §
09:35:38 Q 23.67 0.92 400 §
09:35:38 Q 23.62 0.87 400 §
09:35:38 Q 23.71 0.96 100 §
09:35:38 Q 23.71 0.96 100 §
09:35:38 Q 23.70 0.995 20 §
09:35:38 Q 23.58 0.875 25 §
09:35:38 Q 23.68 0.975 25§
Quelle:https://www.stockwatch.com/Quote/Detail?U:RCEL
https://www.ariva.de/avita_medical-aktie/...split=1&clean_bezug=1
wird weiterhin der Kurse gestellt für "Avita Medical" !
https://www.ariva.de/forum/...l-patentrecht-auf-recell-funhale-384509
sollte dies so bleiben... bislang konnte ich zu einem möglichen delisting nichts finden... wäre dies ggf. eine gute Alternative zu den ADRs... (aber weshalb gibt es Avita Medical und Avita Therapeutics ?)
Over the past one month, investors have witnessed 2 earnings estimate revision lower compared to none higher for the current year. The consensus estimate for RCEL’s has also been on a downward trend over the same time period too, as the estimates have fallen 13% over the last two months.....
..this wasn’t enough,.................... AVITA Medical also has a Zacks Rank #5 (Strong Sell) which puts it into unfortunate company among its peers. So, given all of these factors, i...................nvestors may want to consider exiting this stock now before it falls back to Earth. ..." ENDE Zitat
Quelle:https://finance.yahoo.com/news/...rcel-overbought-drop-130101903.html
Resistance/Support vs. Gaps:http://www.stockta.com/cgi-bin/analysis.pl?symb=RCEL
Quelle:https://cdn-api.markitdigital.com/apiman-gateway/...094df02a206a39ff4
n.b. derzeit können Anteile in der ISIN: US05380C1027 (US-Symbol: RCEL) von mir nicht in mein/e
Wikifolio gekauft werden, da ausschliesslich Kursnotierungen durch L&S via Handelsplatz, für Käufe in Wikifolios möglich sind. Daher habe ich mich nun doch dazu entschlossen, (siehe #20) für diverse von mir geführte BranchenWikifolio, Anteile in der WKN: A2P8DT - ISIN: AU000000AVH4 - US-Symbol: AVHHL zu erwerben. Ich hoffe das stellt sich im Nachhinein nicht doch als Fehler heraus und die Titel sind auch künftig weiterhin handelbar....
Reported total global revenue of $5.1 million in the second quarter of 2021 ended December 31, 2020, a 57% increase over the same quarter in the prior year...... Commercial metrics:
° Procedural volumes were 487 in the second quarter of 2021 versus 496 in the prior quarter ended September 30, 2020.... ° Added 7 new accounts in the second quarter 2021 for a total of 93 accounts
Enrolled nine patients in the pivotal study assessing the use of the RECELL® System to treat stable vitiligo...Second Quarter 2021 Financial Results
Total global revenue was $5.1 million in the second quarter of 2021, compared to $3.3 million for the same quarter last year and flat to the prior quarter ended September 30, 2020....
Gross margin was 84% for the second quarter of 2021, compared with 74% in the same quarter last year, driven largely by the extension of our shelf-life along with lower shipping costs and increased production............Operating expenses were $10.4 million for the second quarter of 2021, compared with $13.4 million in the same quarter last year. ..." ENDE Zitat
Quelle:https://www.stockwatch.com/News/...10211&symbol=RCEL®ion=U
Quelle/n:
https://ir.avitamedical.com/news-releases/...-presentation-53r-annual
http://ameriburn.org/education/annual-meeting/virtual-content/
https://www.stockwatch.com/News/Item/U-z8206629-U!RCEL-20210330/U/RCEL
Procedural volumes were 492 in the third quarter of 2021, compared with 408 in the same period last year, and 487 in the prior quarter ended December 31, 2020;...... Added 6 new burn center accounts in the third quarter 2021 for a total of 99 accounts, or a penetration rate of 73% of the 136 total U.S. burn centers;..... Of the approximate 300 total U.S. burn surgeons:
244 U.S. burn surgeons have been trained and certified with RECELL® through the third quarter of 2021, for a penetration rate of 81%; and........ 147 burn surgeons used RECELL® in the third quarter of 2021, for a penetration rate of nearly 50%...." Ende Zitat
Quelle:https://www.stockwatch.com/News/Item/U-z8236148-U!RCEL-20210513/U/RCEL
Quelle:https://www.stockwatch.com/News/Item/U-z8255089-U!RCEL-20210615/U/RCEL
FDA approved expanded use of the RECELL® System in combination with meshed autografting for the treatment of all sizes of acute full-thickness thermal burn wounds for both pediatric and adult patients.............Full-Year of Fiscal 2021 Highlights............... Total net revenue increased 105% to $29.2 million compared to $14.3 million in the prior year...................... Commercial revenues increased 50% compared to the prior year....... Gross profit margin of 80% compared to 79% in the prior year
Net loss of $26.6 million, or $1.17 per share compared to a net loss of $42.0 million, or $2.07 per share, in the prior year........" ENDE Zitat
Quelle:https://www.stockwatch.com/News/Item/U-z8315923-U!RCEL-20210826/U/RCEL
First Quarter Fiscal Year 2022 Highlights..... Total revenue increased 39% to $7.0 million compared to $5.1 million in the first fiscal quarter of 2021.... Gross profit margin improved 3% to 85% compared to the first fiscal quarter of 2021.... Total operating expenses decreased 18% to $12.3 million compared to $14.9 million in the first fiscal quarter of 2021.... Net loss of $5.9 million, or $0.24 per share compared to a net loss of $10.2 million, or $0.48 per share in the first fiscal quarter of 2021.... As of September 30, 2021, the Company had $60.4 million in cash and cash equivalents and $49.5 million in short-term and long-term marketable securities, and no debt....."Ende Zitat
Source:https://www.stockwatch.com/News/Item/U-z8388525-U!RCEL-20211108/U/RCEL
Links:
https://ir.avitamedical.com/
https://www.barchart.com/stocks/quotes/RCEL/interactive-chart
https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=RCEL (buy)
https://www2.asx.com.au/markets/company/AVH
https://sec.report/Document/0001193125-21-326416/d249729dex992.htm